Biohit
2.04 EUR -1.45%4,641 investors are following this company
Biohit is a medical technology company. The company develops and manufactures laboratory equipment, supplies, and diagnostic analysis systems adapted for research, care, and industrial laboratories. In addition to the main activities, technical support, maintenance, and training services are offered within the mentioned work area. The largest presence is in the Nordic market. The company is headquartered in Helsinki.
P/E (24e)
16.16
EV/EBIT (adj.) (24e)
11.76
P/B (24e)
2.68
Dividend yield-% (24e)
-
Target price
2.40 EUR
Recommendation
Buy
Updated
15.2.2024
NASDAQ Helsinki
BIOBV
Daily low / high price
2.01 / 2.06
EUR
Market cap
30.95M EUR
Turnover
21.12K EUR
Volume
10K
Risk and recommendation
HighRiskLow
SellRecommendationBuy
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
![Antti Siltanen Antti Siltanen](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://core.inderes.fi/sites/default/files/2023-08/Antti_Siltanen.jpg)
Antti Siltanen
Analyst
Latest videos
Financial calendar
Interim report
07.08.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Biohit Healthcare (Hefei) Co., Ltd. | 32.7 % | 29.5 % |
Suovaniemi Osmo Antero | 13.4 % | 56.3 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Daniela Söderström | 18.03.2024 | 8,000EUR |
Panu Hendolin | 18.03.2024 | 8,000EUR |
Premium
This content is for our Premium customers only.
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 7.1 | 9.4 | 11.0 | 13.1 | 15.3 | 17.4 | 19.7 | 22.2 |
growth-% | -29.1 % | 31.4 % | 17.0 % | 19.2 % | 16.9 % | 14.0 % | 13.0 % | 13.0 % |
EBITDA | -1.2 | 0.5 | 1.6 | 2.1 | 2.3 | 2.8 | 3.4 | 4.0 |
EBIT (adj.) | -3.2 | -1.5 | 1.1 | 1.8 | 1.9 | 2.5 | 2.8 | 3.3 |
EBIT | -3.2 | -1.5 | 1.1 | 1.8 | 1.9 | 2.5 | 2.8 | 3.3 |
Profit before taxes | -3.3 | -1.3 | 0.9 | 2.2 | 2.1 | 2.5 | 2.8 | 3.3 |
Net income | -3.3 | -1.5 | 0.6 | 1.8 | 1.9 | 2.0 | 2.3 | 2.6 |
EPS (adj.) | -0.22 | -0.10 | 0.04 | 0.12 | 0.13 | 0.13 | 0.15 | 0.17 |
growth-% | 189.9 % | 9.0 % | 3.4 % | 15.0 % | 16.2 % | |||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.05 |
Dividend ratio | 20.0 % | 30.0 % |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -16.5 % | 5.4 % | 14.7 % | 16.1 % | 15.1 % | 16.2 % | 17.5 % | 18.2 % |
EBIT-% (adj.) | -44.6 % | -15.8 % | 10.3 % | 13.4 % | 12.5 % | 14.2 % | 14.4 % | 14.8 % |
EBIT-% | -44.6 % | -15.8 % | 10.3 % | 13.4 % | 12.5 % | 14.2 % | 14.4 % | 14.8 % |
ROE | -28.3 % | -18.5 % | 8.0 % | 20.6 % | 18.2 % | 15.8 % | 15.5 % | 15.7 % |
ROI | -25.9 % | -17.7 % | 14.3 % | 19.1 % | 16.4 % | 19.8 % | 19.4 % | 19.6 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 2.48 | 1.84 | 1.57 | 1.89 | 2.04 | 2.04 | 2.04 | 2.04 |
Shares | 15.0 | 15.0 | 15.0 | 15.1 | 15.1 | 15.1 | 15.1 | 15.1 |
Market cap | 37.3 | 27.6 | 23.6 | 28.5 | 30.8 | 30.8 | 30.8 | 30.8 |
Enterprise value | 31.6 | 22.3 | 18.3 | 24.0 | 22.4 | 20.8 | 19.1 | 17.4 |
EV/S | 4.4 | 2.4 | 1.7 | 1.8 | 1.5 | 1.2 | 1.0 | 0.8 |
EV/EBITDA | - | 43.8 | 11.4 | 11.4 | 9.7 | 7.4 | 5.6 | 4.3 |
EV/EBIT (adj.) | - | - | 16.3 | 13.7 | 11.8 | 8.4 | 6.7 | 5.3 |
EV/EBIT | - | - | 16.3 | 13.7 | 11.8 | 8.4 | 6.7 | 5.3 |
P/E (adj.) | - | - | 39.3 | 16.3 | 16.2 | 15.6 | 13.6 | 11.7 |
P/E | - | - | 39.3 | 16.3 | 16.2 | 15.6 | 13.6 | 11.7 |
P/B | 4.2 | 3.7 | 3.1 | 3.0 | 2.7 | 2.3 | 2.0 | 1.7 |
P/S | 5.2 | 2.9 | 2.2 | 2.2 | 2.0 | 1.8 | 1.6 | 1.4 |
Dividend yield | 1.5 % | 2.6 % | ||||||
Equity ratio | 81.6 % | 76.7 % | 68.7 % | 73.1 % | 80.4 % | 81.6 % | 82.9 % | 83.8 % |
Gearing ratio | -64.7 % | -72.4 % | -69.8 % | -47.6 % | -72.9 % | -74.4 % | -74.6 % | -74.8 % |
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 6.5 | 6.6 | 13.1 | 7.6 | 7.7 | ||||
EBITDA | 1.7 | 0.4 | 2.1 | 1.2 | 1.1 | ||||
EBIT | 1.5 | 0.3 | 1.8 | 1.0 | 0.9 | ||||
Profit before taxes | 1.7 | 0.5 | 2.2 | 1.1 | 1.0 | ||||
Net income | 1.3 | 0.5 | 1.8 | 1.0 | 0.9 |
ShowingAll content types
BIOHIT STRENGTHENS THE STRATEGIC AND OPERATIONAL PERFORMANCE OF R&D
Constitutive meeting of Biohit Oyj’s Board of Directors
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools